• Phathom reported Q2 2026 net revenues of $74.3 million, up 88% from Q2 2025 and 27% from Q1 2026.
• Net loss narrowed to $17.6 million; non-GAAP adjusted net loss was $0.1 million.
• Operating expenses fell 33% to $63.1 million, driven by lower direct-to-consumer promotional spend and personnel-related costs.
• VOQUEZNA prescriptions filled totaled about 325,000 in the quarter, up 88% year over year; covered prescriptions were about 209,000.
• Full-year 2026 net revenue guidance cut to $310-$325 million; Phase 3 as-needed VOQUEZNA trial in NERD set for first enrollment in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300659PRIMZONEFULLFEED9800749) on July 30, 2026, and is solely responsible for the information contained therein.